Celtein’s focus is on the development of cost-effective, high-performance microfluidic solutions for life sciences. Our device pipeline contains four innovative ELISA/Molecular-based platforms that were engineered to address significant capability gaps in Research and Diagnostic markets. Our first device, the EasyPlex4 (EP4) ELISA-based 4-plex platform, is currently in development with expectations for initial customer trials in mid-to-late 2018.